RxDoctor Payments Data

Trevor Tesch

Physician Assistant · Nampa, IDNPI 1750097754

Payments from drug & device makers

$652in general payments, 2019–2025

Across 30 payments — averaging $21.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$190
  • GSK$161
  • United Therapeutics Corporation$63
  • Insmed, Inc.$53
  • Boehringer Ingelheim$24
  • Merck$22
  • plus $140 from 9 others

What the payments were for

  • Food & beverage$652100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$652 in reported general payments places this provider in the 65th percentile of 1,027 physician assistant providers in Idaho.

See all physician assistant providers in Idaho

Medicare billing

Part B allowed, 2024
$52,470
Medicare patients
287
Services billed
605

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OfevNintedanib Esylate13$170,269
Trelegy ElliptaFluticasone/Umeclidin/Vilanter195$135,600
Breztri AerosphereBudesonide/Glycopyr/Formoterol72$52,723
Dupixent PenDupilumab13$47,409
Breo ElliptaFluticasone/Vilanterol60$26,402
Stiolto RespimatTiotropium Br/Olodaterol Hcl50$25,374
Fluticasone-SalmeterolFluticasone Propion/Salmeterol157$15,015
Spiriva RespimatTiotropium Bromide29$14,489
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr21$7,584
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate42$7,389
Advair HfaFluticasone Propion/Salmeterol17$6,042
Arnuity ElliptaFluticasone Furoate24$5,852
SymbicortBudesonide/Formoterol Fumarate17$4,661
BreynaBudesonide/Formoterol Fumarate31$4,051
Incruse ElliptaUmeclidinium Bromide11$3,813

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat$24$210,13292 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta$161$179,251311 claims
AstraZenecaBreztri Aerosphere, Symbicort$190$57,38489 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,027 physician assistant providers in Idaho.

Other physician assistant in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →